Last reviewed · How we verify

Prevnar 20 — Competitive Intelligence Brief

Prevnar 20 (pneumococcal 20-valent conjugate vaccine (PCV20)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pneumococcal conjugate vaccine. Area: Immunology.

marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) Immunology Vaccine Live · refreshed every 30 min

Target snapshot

Prevnar 20 (pneumococcal 20-valent conjugate vaccine (PCV20)) — Pfizer Inc.. 20-valent pneumococcal conjugate vaccine that elicits immune responses against 20 Streptococcus pneumoniae serotypes

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prevnar 20 TARGET pneumococcal 20-valent conjugate vaccine (PCV20) Pfizer Inc. marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae capsular polysaccharides (20 serotypes) 2021-06-08
PCV13 alone PCV13 alone Korea University Guro Hospital marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide capsule (13 serotypes)
PCV10 full dose PCV10 full dose Epicentre marketed Pneumococcal conjugate vaccine
GSK1024850A (SynflorixTM) GSK1024850A (SynflorixTM) GlaxoSmithKline marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Prevnar13 Prevnar13 GlaxoSmithKline marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide capsule (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F)
Streptococcus pneumoniae serotype 3 Streptococcus pneumoniae serotype 3 University of Oxford marketed Pneumococcal conjugate vaccine Streptococcus pneumoniae serotype 3 capsular polysaccharide
GSK Biologicals' Synflorix™ GSK Biologicals' Synflorix™ GlaxoSmithKline phase 3 Pneumococcal conjugate vaccine Streptococcus pneumoniae polysaccharide antigens (serotypes 1, 5, 6B, 7F, 9V, 14, 19F, 19A, 23F, and others)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Pneumococcal conjugate vaccine class)

  1. GlaxoSmithKline · 12 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
  3. Korea University Guro Hospital · 1 drug in this class
  4. Merck Sharp & Dohme LLC · 1 drug in this class
  5. Papua New Guinea Institute of Medical Research · 1 drug in this class
  6. Pfizer Inc. · 1 drug in this class
  7. Sanofi · 1 drug in this class
  8. University of Minnesota · 1 drug in this class
  9. University of Oxford · 1 drug in this class
  10. Vabiotech · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prevnar 20 — Competitive Intelligence Brief. https://druglandscape.com/ci/prevnar-20. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: